Manejo actual del paciente con CPNM con reordenamiento ALK/ROS1

11 / 36

ASCEND-5
PFS Ceritinib vs Chemotherapy 2nd L
Shaw AT, et al. Lancet Oncol 2017;18:874–86
SAFETY
Grade 3/4 AEs 77 %
Dose reductions due to AEs 37 %
Discontinuation due to AEs 5 %